NDA SUPPLEMENTS FOR CHANGES IN ROUTE OF DRUG SYNTHESIS MUST BE PREAPPROVED BY FDA; PURITY CONCERNS MAY REQUIRE IN VIVO TESTING, AGENCY SAYS IN NDA REWRITE